Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTO-104 in Meniere's Disease
NCT01412177Phase 2Completed
- Sponsor
- Otonomy, Inc.
- Start
- Nov 2013
- Primary completion
- Mar 2015
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Otividex in Meniere's disease (MD), sponsored by Otonomy, Inc.. Started Nov 2013; status: completed.
02
Drugs
Otividex
03
Conditions
Meniere's disease (MD)
Beyond the preview
Go deeper on NCT01412177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01412177.